Pharmacotherapy in benign prostatic hyperplasia.
Symptomatic bladder outlet obstruction due to benign prostatic hyperplasia (BPH) has been conventionally treated by transurethral resection. In recent years, a better understanding of the natural history and pathophysiology of BPH coupled with significant morbidity of prostate surgery has led to renewed interest in the medical therapy of BPH. Both alpha 1 blockers and 5 alpha-reductase inhibitors have been shown to be effective in recent clinical trials in the treatment of BPH. Both these drugs are safe and their side effects reversible. Medical therapy has a bigger role to play now especially for those high risk patients with moderate to severe symptoms of BPH. Further development of more effective alpha blockers and anti-androgens with less side effects would make pharmacotherapy an even more attractive alternative than the more invasive procedures.
Tan
E C
EC
Mount Elizabeth Medical Centre, Singapore.
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy*
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists